Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandra M Nanzer

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
American Journal of Respiratory and Critical Care Medicine|February 25, 2026
Fractional Exhaled Nitric Oxide as a Novel Biomarker of Relapse in Eosinophilic Granulomatosis with PolyangiitisFrancesca Cefaloni, Anne-Catherine Maynard-Paquette, Ajerico Del Rosario, et al.
Allergy|May 1, 2022
COVID-19 in the absence of eosinophils: The outcome of confirmed SARS-CoV-2 infection whilst on treatment with benralizumabCharles H R Francis, Andrew P Hearn, Sharenja Ratnakumar, et al.
The European Respiratory Journal|February 16, 2020
Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthmaGráinne d'Ancona, Joanne Kavanagh, Cris Roxas, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 22, 2026
Application of T2 Biomarkers to Support Steroid Stewardship in Severe Asthma - a retrospective cohort studyAlexandra M Nanzer, Jodie Lam, Cris Roxas, et al.
Chest|April 11, 2020
Real-World Effectiveness and the Characteristics of a "Super-Responder" to Mepolizumab in Severe Eosinophilic AsthmaJoanne E Kavanagh, Grainne d'Ancona, Maria Elstad, et al.
Clinical Endocrinology|August 22, 2006
PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptorMichelle N Emery, Chrysanthia Leontiou, Sarah E Bonner, et al.
The Journal of Allergy and Clinical Immunology. in Practice|April 7, 2024
Long-Term Effectiveness of Anti-IL-4R Therapy Following Suboptimal Response to Anti-IL-5/5R Therapy in Severe Eosinophilic AsthmaJessica Gates, Andrew Hearn, Tom Mason, et al.
Allergy|January 12, 2021
Adherence to inhaled corticosteroids and clinical outcomes following a year of benralizumab therapy for severe eosinophilic asthmaGrainne d'Ancona, Joanne E Kavanagh, Jaideep Dhariwal, et al.
Allergy|December 10, 2020
Benralizumab after sub-optimal response to mepolizumab in severe eosinophilic asthmaJoanne E Kavanagh, Andrew P Hearn, Grainne d'Ancona, et al.
The Journal of Allergy and Clinical Immunology|March 17, 2015
Distinct endotypes of steroid-resistant asthma characterized by IL-17A(high) and IFN-γ(high) immunophenotypes: Potential benefits of calcitriolEmma S Chambers, Alexandra M Nanzer, Paul E Pfeffer, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
American Journal of Respiratory and Critical Care Medicine|February 25, 2026
Fractional Exhaled Nitric Oxide as a Novel Biomarker of Relapse in Eosinophilic Granulomatosis with PolyangiitisFrancesca Cefaloni, Anne-Catherine Maynard-Paquette, Ajerico Del Rosario, et al.
Allergy|May 1, 2022
COVID-19 in the absence of eosinophils: The outcome of confirmed SARS-CoV-2 infection whilst on treatment with benralizumabCharles H R Francis, Andrew P Hearn, Sharenja Ratnakumar, et al.
The European Respiratory Journal|February 16, 2020
Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthmaGráinne d'Ancona, Joanne Kavanagh, Cris Roxas, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 22, 2026
Application of T2 Biomarkers to Support Steroid Stewardship in Severe Asthma - a retrospective cohort studyAlexandra M Nanzer, Jodie Lam, Cris Roxas, et al.
Chest|April 11, 2020
Real-World Effectiveness and the Characteristics of a "Super-Responder" to Mepolizumab in Severe Eosinophilic AsthmaJoanne E Kavanagh, Grainne d'Ancona, Maria Elstad, et al.
Clinical Endocrinology|August 22, 2006
PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptorMichelle N Emery, Chrysanthia Leontiou, Sarah E Bonner, et al.
The Journal of Allergy and Clinical Immunology. in Practice|April 7, 2024
Long-Term Effectiveness of Anti-IL-4R Therapy Following Suboptimal Response to Anti-IL-5/5R Therapy in Severe Eosinophilic AsthmaJessica Gates, Andrew Hearn, Tom Mason, et al.
Allergy|January 12, 2021
Adherence to inhaled corticosteroids and clinical outcomes following a year of benralizumab therapy for severe eosinophilic asthmaGrainne d'Ancona, Joanne E Kavanagh, Jaideep Dhariwal, et al.
Allergy|December 10, 2020
Benralizumab after sub-optimal response to mepolizumab in severe eosinophilic asthmaJoanne E Kavanagh, Andrew P Hearn, Grainne d'Ancona, et al.
The Journal of Allergy and Clinical Immunology|March 17, 2015
Distinct endotypes of steroid-resistant asthma characterized by IL-17A(high) and IFN-γ(high) immunophenotypes: Potential benefits of calcitriolEmma S Chambers, Alexandra M Nanzer, Paul E Pfeffer, et al.
Pageof 4